IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model - Wikidata - thesis-toulmin - TriplyDB

IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model

IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model

http://www.wikidata.org/entity/Q35108924

about

T Helper Cell Subsets in Clinical Manifestations of Psoriasis Skin models for the testing of transdermal drugs Keratinocyte detachment-differentiation connection revisited, or anoikis-pityriasi nexus redux The expression and regulation of chemerin in the epidermis.CARD14 expression in dermal endothelial cells in psoriasis.Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis.Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection.Comparative and Evolutionary Analysis of the Interleukin 17 Gene Family in Invertebrates.BubbleGUM: automatic extraction of phenotype molecular signatures and comprehensive visualization of multiple Gene Set Enrichment Analyses.IL-17 sequestration via salivary gland gene therapy in a mouse model of Sjogren's syndrome suppresses disease-associated expression of the putative autoantigen Klk1b22 Isolation of All CD44 Transcripts in Human Epidermis and Regulation of Their Expression by Various Agents.CCAAT/Enhancer-binding protein β promotes pathogenesis of EAE.Update on psoriasis immunopathogenesis and targeted immunotherapy.Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.The Membrane-Bound Form of IL-17A Promotes the Growth and Tumorigenicity of Colon Cancer Cells.Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses Tissue-engineered human psoriatic skin supplemented with cytokines as an in vitro model to study plaque psoriasis.Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.IL-17 Signaling: The Yin and the Yang.IL-17 and IL-22 in immunity: Driving protection and pathology.Yin and yang of interleukin-17 in host immunity to infection.Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes.Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models.Models in the Research Process of Psoriasis.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation.Scanning the Immunopathogenesis of Psoriasis.The role of interleukin-17 in mouse models of atopic dermatitis and contact dermatitis.The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.A revolutionary therapeutic approach for psoriasis: bispecific biological agents.A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice.Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment.

P2860

Q28069848-8CAFC501-923A-4AF6-B0C1-B67196B23A91 Q28074471-0970AA7F-F6CF-40E2-805E-D8F8F6FF7421 Q28539945-EAC9D2E9-F511-4ED7-931E-6EB326C4ADE9 Q35058811-47AB4A47-2655-4EAB-A8E4-CDD236A90C27 Q35392242-A255E759-5780-4CDD-AC11-9F3352AA2B3A Q35522947-13D8DB0E-E998-4274-B4E6-EE7A5BAD7458 Q35539472-E69A0BCA-1947-4369-B839-7197E1CEAEF6 Q35720469-2621B552-EDE2-4BC4-9DE5-7907B0E96D8C Q35813186-8A88A521-629B-4E2F-8288-582E43C7E3D4 Q35923212-CC0D0875-9CAB-4DF1-A3B5-4872ED1A6957 Q36098905-0C9B6ABA-99C1-42E1-9623-7648547755AE Q36249964-04015382-FACD-4752-BF16-2B8FEFA4C3B3 Q36445919-23BFA085-D6E6-44CD-81C4-2DD946D49A3B Q36484115-A538014F-9FCB-484B-9F37-C498B10AF9BA Q36514683-0525A20A-1F07-4CEC-9637-54848717F55F Q37121866-2909250A-47CC-4CF8-B456-2B70221C61D6 Q38436135-EA36A17E-5B3B-45D7-8AC5-6FBFE86F74C5 Q38443852-825380D3-B115-4D48-80FC-610ABFE83F5E Q38445314-DA6A96D6-47A9-482C-ACF0-DC76057EC113 Q38635555-D35C0253-F1B4-4B5A-A9CF-7E13672097B1 Q38663614-10121CC7-F2E5-4E35-B62D-F0075FD6C6B6 Q38674266-8CE4BF8A-44F5-428F-85E7-F74C72A58E83 Q38856226-7741CD30-D05B-4E15-8CC3-84C95C774976 Q38968548-DC1F6F3E-881A-4065-990B-E62638969C63 Q38969026-A9E557A6-F5E4-4BA6-A73F-F873CE8ADBC8 Q39158530-3ED20B14-6F73-4F06-A409-ED638B1B16EF Q39179415-D603FE47-DD7F-48B0-9B8C-4B0FB7B51353 Q39438071-D42A015C-68E3-44B6-98BB-154BD0BFCEF5 Q39477242-8092CD59-3027-4AA2-A8AC-272894FDB832 Q39947458-9D3B0B6E-39C9-43C0-8954-23218D74B601 Q41717499-BFC1D20A-0B0C-48D7-8374-989F770D809A Q47181496-8B46BC95-6F6F-4DEB-B68C-DCCC8414C00E Q47704613-25F5227F-AD08-44BE-838A-30037D07D1C7 Q48179370-F4E64CB1-D905-4ECF-88F9-453832A7EBA7 Q48278167-2BC1CA60-3E2F-4454-9976-5786316E6141 Q48327175-A50891E6-DE98-4DE0-BAAB-D8F9EEFBDB7F Q50436409-6D15811B-EA47-48BF-AC2B-EFA39B1C1658 Q54422386-1856AF01-50BE-47F2-BD3D-7EB93624D65F Q55048045-ECA8549D-AE37-4EDE-8CF7-909D61FF39B3 Q55115632-76BE9A8A-8CA1-4840-8A6D-554072C5E8C8

P2860

IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model

http://www.wikidata.org/entity/Q35108924

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

IL-17 induces an expanded rang ...... stituted human epidermis model

@ast

IL-17 induces an expanded rang ...... stituted human epidermis model

@en

type

label

IL-17 induces an expanded rang ...... stituted human epidermis model

@ast

IL-17 induces an expanded rang ...... stituted human epidermis model

@en

prefLabel

IL-17 induces an expanded rang ...... stituted human epidermis model

@ast

IL-17 induces an expanded rang ...... stituted human epidermis model

@en

P1433

Q35108924-CB12A6AA-AD74-4EF9-8841-5D1BAB16EFE8

P1476

Q35108924-293D9FC8-0400-416C-918A-43A6B33969AE

P2093

Q35108924-048B8D9F-B171-4F6E-963C-B1413344927B

Q35108924-0B75DD76-EB31-4434-8503-E70694FB8547

Q35108924-13358BA1-1570-47D3-94F2-826C2198819D

Q35108924-4DD3BE64-98E6-4AEB-ABE4-E3638C2FFCB9

Q35108924-71FB1335-9A60-438B-930E-DC7B48CDA42A

Q35108924-78561B05-A68E-4E6A-B18B-2F423481EA80

Q35108924-8AC89164-E475-4515-99FF-AB094A9414BE

Q35108924-914A961A-F098-4CC0-BC1D-7921E903160B

Q35108924-916CD6E7-C91C-462A-8838-87898F868600

Q35108924-ACC6107E-8EB4-4613-8888-AC4FA8170FA0

P2860

Q35108924-00AA2BBF-9F7F-4A3E-827C-316E58EE4521

Q35108924-071239C3-B907-4677-B1EE-740994839576

Q35108924-07126121-66B3-4CF7-B428-8A15BF1E4999

Q35108924-0B8F40C5-DDD4-4018-A78F-08D004B6D830

Q35108924-0B963BE4-B800-46E1-9916-68608D24C20C

Q35108924-0EC42B48-3256-4600-BCF0-BA7CB2336EC2

Q35108924-1045A1BD-E5B7-44ED-9976-8E3791314826

Q35108924-1AF395B5-7196-47A8-B80B-51A10456A6B9

Q35108924-1E68ED3B-6018-451F-BFD9-47AEF861C5FF

Q35108924-21D12133-EFDB-44A8-AA89-DEA7F4078999

P304

Q35108924-58751BEE-2341-4BAF-8263-ADA668C8B347

P31

Q35108924-E6413BC1-059B-4B1C-ADDA-DDB148EF201F

P356

Q35108924-AE35009B-ACAE-487A-A6A9-0C6D3D169C2C

P407

Q35108924-54078665-B742-4D4D-9278-B29EDE809D7C

P433

Q35108924-17D9DDFB-AB72-4217-859F-2D04B3D37E9E

P478

Q35108924-3109F73E-EC23-44DE-B233-DDDBD4DE33CF

P577

Q35108924-B5FF1440-3D53-43E0-9043-8C868CF6D4B4

P5875

Q35108924-A82B2490-7BA6-49D1-A754-69DF4E3DEC0C

P698

Q35108924-9945A418-9468-42BD-A5B6-276147144C24

P932

Q35108924-61D35993-A9B8-49FB-9797-001D5D76DD25

P356

JOURNAL.PONE.0090284

P1433

P1476

IL-17 induces an expanded rang ...... stituted human epidermis model

@en

P2093

Andrea Chiricozzi

http://www.w3.org/2001/XMLSchema#string

Emma Guttman-Yassky

http://www.w3.org/2001/XMLSchema#string

Hiroshi Mitsui

http://www.w3.org/2001/XMLSchema#string

Irma Cardinale

http://www.w3.org/2001/XMLSchema#string

James G Krueger

http://www.w3.org/2001/XMLSchema#string

Judilyn Fuentes-Duculan

http://www.w3.org/2001/XMLSchema#string

Kathleen M Bonifacio

http://www.w3.org/2001/XMLSchema#string

Kristine E Nograles

http://www.w3.org/2001/XMLSchema#string

Leanne M Johnson-Huang

http://www.w3.org/2001/XMLSchema#string

Mayte Suárez-Fariñas

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression

Structure and signalling in the IL-17 receptor family

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

Harshlight: a "corrective make-up" program for microarray chips.

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

P304

e90284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0090284

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260448500

http://www.w3.org/2001/XMLSchema#string

P698

24587313

http://www.w3.org/2001/XMLSchema#string

P932

3938679

http://www.w3.org/2001/XMLSchema#string